FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1657226110> ?p ?o ?g. }

• W1657226110 endingPage "779" @default.
• W1657226110 startingPage "771" @default.
• W1657226110 abstract "No AccessJournal of UrologyInvestigative Urology1 Mar 2016CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1 Anuja Sathe, Nicole Koshy, Sebastian C. Schmid, Mark Thalgott, Sarah M. Schwarzenböck, Bernd J. Krause, Per S. Holm, Juergen E. Gschwend, Margitta Retz, and Roman Nawroth Anuja SatheAnuja Sathe More articles by this author , Nicole KoshyNicole Koshy More articles by this author , Sebastian C. SchmidSebastian C. Schmid More articles by this author , Mark ThalgottMark Thalgott More articles by this author , Sarah M. SchwarzenböckSarah M. Schwarzenböck More articles by this author , Bernd J. KrauseBernd J. Krause More articles by this author , Per S. HolmPer S. Holm More articles by this author , Juergen E. GschwendJuergen E. Gschwend More articles by this author , Margitta RetzMargitta Retz More articles by this author , and Roman NawrothRoman Nawroth More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.08.082AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The retinoblastoma signaling network is frequently altered in advanced bladder cancer. We investigated the potential of CDK4/6 as a therapeutic target and determined biomarkers for patient stratification. Materials and Methods: Genetic alterations were analyzed using public databases, including TCGA (The Cancer Genome Atlas), COSMIC (Catalogue of Somatic Mutations in Cancer) and CCLE (Cancer Cell Line Encyclopedia). Effects of the CDK4/6-inhibitor PD-0332991 or LY2835219 were examined in 10 bladder cancer cell lines by immunoblot, cell viability, apoptosis and cell cycle progression. Efficacy of the PD-0332991 and cisplatin combination was analyzed using the combination index. Gene expression level was determined by quantitative polymerase chain reaction. Cytomegalovirus promoter regulated recombinant retinoblastoma was used for reconstitution. Three-dimensional xenografts were grown on chicken chorioallantoic membrane and analyzed by measuring tumor weight and immunohistochemical expression of total retinoblastoma and Ki-67. Results: PD-0332991 treatment decreased the proliferation of retinoblastoma positive bladder cancer cell lines and was synergistic in combination with cisplatin. PD-0332991 or LY2835219 treatment decreased the phosphorylation, total protein and transcript level of retinoblastoma. Treatment resulted in a decrease in E2F target gene expression (CCNA2 and CCNE2) and cell cycle progression from G0/G1 to the S-phase but did not affect apoptosis. In retinoblastoma negative cells reconstituted with recombinant retinoblastoma PD-0332991 affected only phosphorylation and not the total retinoblastoma level. These cells remained resistant to treatment. In 3-dimensional retinoblastoma xenografts, treatment resulted in reduced tumor weight and decreased expression of total retinoblastoma and Ki-67. Conclusions: We provide preclinical evidence that CDK4/6 inhibition is a potential therapeutic strategy for retinoblastoma positive bladder cancer that probably acts by negatively regulating retinoblastoma transcription. References 1 : Cancer statistics, 2015. CA Cancer J Clin2015; 65: 5. Google Scholar 2 : EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol2014; 65: 778. Google Scholar 3 : Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol2005; 23: 4602. Google Scholar 4 : Comprehensive molecular characterization of urothelial bladder carcinoma. Nature2014; 507: 315. Google Scholar 5 : The hallmarks of cancer. Cell2000; 100: 57. Google Scholar 6 : Targeting the RB-pathway in cancer therapy. Clin Cancer Res2010; 16: 1094. Google Scholar 7 : Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem2001; 276: 16617. Google Scholar 8 : Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res2014; 27: 590. Google Scholar 9 : p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol2012; 14: 870. Google Scholar 10 : Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res2011; 17: 1591. Google Scholar 11 : PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res2009; 11: R77. Google Scholar 12 : Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene2010; 29: 4018. Google Scholar 13 : Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci U S A2010; 107: 11501. Google Scholar 14 : The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov2015; 14: 130. Google Scholar 15 : Palbociclib: first global approval. Drugs2015; 75: 543. Google Scholar 16 : Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer2014; 111: 2103. Google Scholar 17 : Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res2010; 70: 440. Google Scholar 18 : Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal2013; 6: pl1. Google Scholar 19 : COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res2011; 39: D945. Google Scholar 20 : The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature2012; 483: 603. Google Scholar 21 : S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One2011; 6: e27509. Google Scholar 22 : Semi-quantitative immunohistochemical assay versus oncotype DX((R)) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol2012; 25: 869. Google Scholar 23 : Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc2008; 3: 1101. Google Scholar 24 : Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer1995; 72: 683. Google Scholar 25 : Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun2011; 413: 62. Google Scholar 26 : The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol2015; 16: 25. Google Scholar 27 : Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res2001; 7: 2168. Google Scholar 28 : Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther2004; 3: 1427. Google Scholar 29 : Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood2006; 108: 1744. Google Scholar 30 : PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis. Oncol Lett2014; 7: 1673. Google Scholar © 2016 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 195Issue 3March 2016Page: 771-779Supplementary Materials Advertisement Copyright & Permissions© 2016 by American Urological Association Education and Research, Inc.Keywordspalbocicliburinary bladder neoplasmscyclin-dependent kinase inhibitor proteinsbiological markersretinoblastomaAcknowledgmentsDr. W. A. Schulz, Heinrich-Heine-University, Düsseldorf, Germany, provided 253J, 639V, VmCUB1 and 5637. Bob Weinberg provided RcCMV/Rb.MetricsAuthor Information Anuja Sathe More articles by this author Nicole Koshy More articles by this author Sebastian C. Schmid More articles by this author Mark Thalgott More articles by this author Sarah M. Schwarzenböck More articles by this author Bernd J. Krause More articles by this author Per S. Holm More articles by this author Juergen E. Gschwend More articles by this author Margitta Retz More articles by this author Roman Nawroth More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1657226110 created "2016-06-24" @default.
• W1657226110 creator A5003688542 @default.
• W1657226110 creator A5008903814 @default.
• W1657226110 creator A5010135926 @default.
• W1657226110 creator A5014284729 @default.
• W1657226110 creator A5024163450 @default.
• W1657226110 creator A5029152210 @default.
• W1657226110 creator A5045898446 @default.
• W1657226110 creator A5083722051 @default.
• W1657226110 creator A5084912027 @default.
• W1657226110 creator A5089218170 @default.
• W1657226110 date "2016-03-01" @default.
• W1657226110 modified "2023-10-16" @default.
• W1657226110 title "CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1" @default.
• W1657226110 cites W1976119535 @default.
• W1657226110 cites W1979426842 @default.
• W1657226110 cites W1984245506 @default.
• W1657226110 cites W1985850253 @default.
• W1657226110 cites W1989773675 @default.
• W1657226110 cites W2007174523 @default.
• W1657226110 cites W2034269086 @default.
• W1657226110 cites W2036013203 @default.
• W1657226110 cites W2043398720 @default.
• W1657226110 cites W2043761487 @default.
• W1657226110 cites W2052987836 @default.
• W1657226110 cites W2057272791 @default.
• W1657226110 cites W2058828565 @default.
• W1657226110 cites W2061818721 @default.
• W1657226110 cites W2068523052 @default.
• W1657226110 cites W2082563214 @default.
• W1657226110 cites W2096439168 @default.
• W1657226110 cites W2098864119 @default.
• W1657226110 cites W2099380351 @default.
• W1657226110 cites W2103257412 @default.
• W1657226110 cites W2114570899 @default.
• W1657226110 cites W2114843025 @default.
• W1657226110 cites W2144241792 @default.
• W1657226110 cites W2144790402 @default.
• W1657226110 cites W2148345265 @default.
• W1657226110 cites W2153985422 @default.
• W1657226110 cites W2154626333 @default.
• W1657226110 cites W2170552969 @default.
• W1657226110 cites W2170705825 @default.
• W1657226110 doi "https://doi.org/10.1016/j.juro.2015.08.082" @default.
• W1657226110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26318986" @default.
• W1657226110 hasPublicationYear "2016" @default.
• W1657226110 type Work @default.
• W1657226110 sameAs 1657226110 @default.
• W1657226110 citedByCount "35" @default.
• W1657226110 countsByYear W16572261102015 @default.
• W1657226110 countsByYear W16572261102016 @default.
• W1657226110 countsByYear W16572261102017 @default.
• W1657226110 countsByYear W16572261102018 @default.
• W1657226110 countsByYear W16572261102019 @default.
• W1657226110 countsByYear W16572261102020 @default.
• W1657226110 countsByYear W16572261102021 @default.
• W1657226110 countsByYear W16572261102022 @default.
• W1657226110 countsByYear W16572261102023 @default.
• W1657226110 crossrefType "journal-article" @default.
• W1657226110 hasAuthorship W1657226110A5003688542 @default.
• W1657226110 hasAuthorship W1657226110A5008903814 @default.
• W1657226110 hasAuthorship W1657226110A5010135926 @default.
• W1657226110 hasAuthorship W1657226110A5014284729 @default.
• W1657226110 hasAuthorship W1657226110A5024163450 @default.
• W1657226110 hasAuthorship W1657226110A5029152210 @default.
• W1657226110 hasAuthorship W1657226110A5045898446 @default.
• W1657226110 hasAuthorship W1657226110A5083722051 @default.
• W1657226110 hasAuthorship W1657226110A5084912027 @default.
• W1657226110 hasAuthorship W1657226110A5089218170 @default.
• W1657226110 hasConcept C121608353 @default.
• W1657226110 hasConcept C126322002 @default.
• W1657226110 hasConcept C138885662 @default.
• W1657226110 hasConcept C143998085 @default.
• W1657226110 hasConcept C179926584 @default.
• W1657226110 hasConcept C2780352672 @default.
• W1657226110 hasConcept C41895202 @default.
• W1657226110 hasConcept C502942594 @default.
• W1657226110 hasConcept C71924100 @default.
• W1657226110 hasConceptScore W1657226110C121608353 @default.
• W1657226110 hasConceptScore W1657226110C126322002 @default.
• W1657226110 hasConceptScore W1657226110C138885662 @default.
• W1657226110 hasConceptScore W1657226110C143998085 @default.
• W1657226110 hasConceptScore W1657226110C179926584 @default.
• W1657226110 hasConceptScore W1657226110C2780352672 @default.
• W1657226110 hasConceptScore W1657226110C41895202 @default.
• W1657226110 hasConceptScore W1657226110C502942594 @default.
• W1657226110 hasConceptScore W1657226110C71924100 @default.
• W1657226110 hasIssue "3" @default.
• W1657226110 hasLocation W16572261101 @default.
• W1657226110 hasLocation W16572261102 @default.
• W1657226110 hasOpenAccess W1657226110 @default.
• W1657226110 hasPrimaryLocation W16572261101 @default.
• W1657226110 hasRelatedWork W1975217245 @default.
• W1657226110 hasRelatedWork W1979321249 @default.
• W1657226110 hasRelatedWork W2042254975 @default.
• W1657226110 hasRelatedWork W2415761310 @default.
• W1657226110 hasRelatedWork W2421821834 @default.

• next